Journal article
PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer
V Tran, A Hong, T Sutherland, K Taubman, SF Lee, D Lenaghan, K Sethi, NM Corcoran, N Lawrentschuk, H Woo, L Tarlinton, D Bolton, T Spelman, L Thomas, R Booth, J Hegarty, E Perry, LM Wong
BMJ Open | Published : 2022
Abstract
Introduction Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has emerged as valuable imaging to assessing metastatic disease in prostate malignancy. However, there has been limited studies exploring the utility PSMA-PET as primary imaging assessing for index lesions prior to biopsy. The primary objective of this study is to compare the diagnostic accuracy of 18-fluorine PSMA (18F DCFPyL PSMA) PET scans to multiparametric MRI (mpMRI) to detect primary prostate cancer at prostate biopsy. Methods and analysis The PEDAL trial is a multicentre, prospective, single-arm, paired comparison, non-randomised phase III trial in subjects considered for diagnostic prostate biops..
View full abstractGrants
Funding Acknowledgements
This clinical trial is supported by Cyclotek (Aust) Pty Ltd and their key partners, the Australian Government as part of its CRC Projects Program, General Electrical Healthcare, Macquarie University and the EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare. We are also grateful for philanthropic donations from Reese Limited, the Pitcher and Cicutto families via the St Vincent's Foundation.